Hemizygous Disruption of Cdc25A Inhibits Cellular Transformation and Mammary Tumorigenesis in Mice

Dipankar Ray,1 Yasuhisa Terao,2 Dipali Nimbalker,1 Hiroyuki Hirai,1 Evan C. Osmundson,1,3 Xianghong Zou,4 Roberta Franks, Konstantin Christov,4 and Hiroaki Kiyokawa1,2,3

1Department of Molecular Pharmacology and Biological Chemistry and 2Robert H. Lurie Comprehensive Cancer Center, Northwestern University, and 3Department of Biochemistry and Molecular Genetics, Research Resources Center, and 4Department of Surgical Oncology, University of Illinois College of Medicine, Chicago, Illinois

Abstract

Cdc25A phosphatase activates multiple cyclin-dependent kinases (CDK) during cell cycle progression. Inactivation of Cdc25A by ubiquitin-mediated degradation is a major mechanism of DNA damage-induced S-G2 checkpoint. Although increased Cdc25A expression has been reported in various human cancer tissues, it remains unclear whether Cdc25A activation is a critical rate-limiting step of carcinogenesis. To assess the role for Cdc25A in cell cycle control and carcinogenesis, we used a Cdc25A-null mouse strain we recently generated. Whereas Cdc25A+/− mice exhibit early embryonic lethality, Cdc25A−/− mice show no appreciable developmental defect. Cdc25A−/− mouse embryonic fibroblasts (MEF) exhibit normal kinetics of cell cycle progression at early passages, modestly enhanced G2 checkpoint response to DNA damage, and shortened proliferative life span, compared with wild-type MEFs. Importantly, Cdc25A+/− MEFs are significantly resistant to malignant transformation induced by coexpression of H-rasV12 and a dominant negative p53 mutant. The rate-limiting role for Cdc25A in transformation is further supported by decreased transformation efficiency in MCF-10A human mammary epithelial cells stably expressing Cdc25A small interfering RNA. Consistently, Cdc25A−/− mice show substantially prolonged latency in mammary tumorigenesis induced by MMTV-H-ras or MMTV-neu transgene, whereas MMTV-neu−/− induced tumorigenesis is not significantly affected by Cdc25A heterozygosity. Mammary tissues of Cdc25A+/−;MMTV-neu mice before tumor development display less proliferative response to the oncogene with increased tyrosine phosphorylation of CDK1/2, but show no significant change in apoptosis. These results suggest that Cdc25A plays a rate-limiting role in transformation and tumor initiation mediated by ras activation. [Cancer Res 2007;67(14):6605–11]

Introduction

Cyclin-dependent kinases (CDK) play central roles in promoting progression of the cell cycle in all eukaryotic cells (1). CDK activity undergoes multiple layers of regulatory processes, including association with cyclins and inhibitors and post-translational modifications of CDK proteins, such as phosphorylation and dephosphorylation. Although phosphorylation of the T loop, e.g., Thr161 of CDK1, is required for full activation of CDKs, phosphorylation around the ATP binding site, e.g., Tyr15 of CDK1, is inhibitory on the CDK activity. The inhibitory phosphorylation of CDKs is mediated by Wee1 or Myt1 kinases, and dephosphorylation of the sites is catalyzed by Cdc25 family phosphatases (2). This inhibitory phosphorylation plays important roles in controlling the timing of CDK activation. CDK2 activated by association with cyclin E and cyclin A governs initiation and completion of DNA replication. Cdc25A-mediated dephosphorylation of CDK2 is critical for appropriate progression of S phase. CDK1 activated by cyclin A and cyclin B plays an essential role in initiation and completion of mitosis. All CDC25 phosphatases, i.e., CDC25A, CDC25B, and CDC25C, are likely to collaborate in timely activation of CDK1-cyclin A and CDK1-cyclin B during G2-M transition. However, cells with compound disruption of CDC25B and CDC25C display minimum change in cell cycle progression (3). In contrast, CDC25A may play a nonredundant role in CDK1 activation (4). Knockdown of CDC25A by RNA interference delays both G1-S and G2-M transitions (5), whereas overexpression of CDC25A can induce aberrant mitotic events (6).

Inactivation of CDC25 phosphatases is a major mechanism of cell cycle checkpoint (2). In response to DNA damage, activated CHK1 and CHK2 phosphorylate CDC25A and CDC25C (7, 8). It has been shown that CHK2-mediated phosphorylation inactivates CDC25C by cytoplasmic sequestration (7). On the other hand, CHK1-mediated CDC25A phosphorylation results in ubiquitination by the Skp1-Cullin-β-TrCP E3 complex and rapid proteasome-dependent degradation (9, 10). The CHK1-mediated CDC25A degradation leads to cell cycle arrest in S or G2 phase. This is an acute response to DNA damage without employing new transcription or translation, in contrast to p53-dependent checkpoint responses involving transcription of p21(Cip1) (11) and 14-3-3σ (12, 13). CHK1 predominantly regulates cellular levels of CDC25A protein even during unperturbed cell cycle progression. Deregulation of checkpoint pathways is thought to play a key role in tumor progression. For instance, loss of the proximal checkpoint kinase ATM, which functions upstream of CHK1/2, strongly predisposes humans and mice to tumorigenesis (14, 15). Haploinsufficiency of another proximal kinase, ATR, promotes tumorigenesis in mice with defective DNA-mismatch repair (16). Furthermore, Chk1 heterozygous mice exhibit enhanced tumorigenesis induced by Wnt-1 (17). Consistently with the notion that CDC25A is a major target of the Chk1 pathway, cellular Cdc25A levels are increased in Chkl heterozygous mice (18). CDC25A expression is significantly increased in a variety of human cancers, including head and neck, liver, thyroid, breast, ovary, and lung cancers (19–25). These observations suggest that tumor-suppressive
action of the checkpoint pathway may depend largely on control of CDC25A expression within proper levels. In the present study, we examined whether CDC25A is rate limiting for cellular transformation and in vivo tumorigenesis using a newly generated Cdc25A-null mouse line.

Materials and Methods

Generation of mouse lines. Cdc25A mutant mouse lines were generated by gene targeting in a 129/sv mouse embryonic stem (ES) cell line, GS-1, followed by injection into C57Bl/6 mouse embryos at the blastocyst stage, as previously described (26). Chimeras were then bred with wild-type C57Bl/6 mice to generate germ line heterozygous mutants. Two ES clones, 2G6 and 2E11, went germ line, and homozygotes from both clones exhibited similar embryonic lethal phenotype. Therefore, mice from 2G6 were further characterized for this study. MMTV-H-ras, MMTV-neu, and MMTV-myc mice were described previously (27, 28). Mice were maintained according to protocols approved by the Institutional Animal Care Committees at Northwestern University and University of Illinois according to the AAALAS regulation. The primers used for genotyping PCR are SW39, 5′-ATATTTGCT-GAAGAGCTTGGCGG-3′; HK307, 5′-CTCTTGTTACCTGTGTGTTAG-GATTGTTG-3′; and HK521, 5′-CTCTTCTAGTACTGGATGTTATATGGA-3′. The annealing temperature used for the 35-cycle PCR reaction was 62°C. To detect tumorigenesis, each mouse was physically examined twice a week, and the date of detecting palpable tumors was recorded. Mice were sacrificed when diameters of primary tumors reached 2 cm. For immunohistochemical analysis of proliferating cells, mice were injected i.p. with bromodeoxyuridine (BrdUrd, 50 μg/g body weight) at 2 h before sacrifice.

Cell cultures. Mouse embryonic fibroblasts (MEF) were isolated from day 12.5 mouse embryos and cultured as previously described (29). To determine cumulative population doublings, MEFs were cultured according to a 3T3 protocol, inoculated at the density of 3 × 10^4 per 25-cm² area (60-mm dish), and subcultured every 3 days. The population doubling level during each passage was calculated according to the formula: log[final cell number/initial cell number]. MEF-10A cells were cultured in DMEM/F12 supplemented with 5% heat-inactivated horse serum, 10 μg/mL insulin, 0.5 μg/mL hydrocortisone, 20 ng/mL recombinant epithelial growth factor, 2 mmol/L L-glutamine, and 100 μg/mL penicillin/streptomycin. The sequences of small interfering RNAs (siRNA) 1 and 3 for targeting Cdc25A were 5′-AACCUUGACAACCGAUGCA-3′ (residues 179–198) and 5′-CTTCTGTTACTGTGTGTAG-GATTGTTG-3′; and HK507, 5′-CTCTTCTAGTACTGGATGTTATATGGA-3′. To determine cumulative population doublings, MEFs were cultured according to a 3T3 protocol, inoculated at the density of 3 × 10^4 per 25-cm² area (60-mm dish), and subcultured every 3 days. The population doubling level during each passage was calculated according to the formula: log[final cell number/initial cell number]. MEF-10A cells were cultured in DMEM/F12 supplemented with 5% heat-inactivated horse serum, 10 μg/mL insulin, 0.5 μg/mL hydrocortisone, 20 ng/mL recombinant epithelial growth factor, 2 mmol/L L-glutamine, and 100 μg/mL penicillin/streptomycin. The sequences of small interfering RNAs (siRNA) 1 and 3 for targeting Cdc25A were 5′-AACCUUGACAACCGAUGCA-3′ (residues 179–198) and 5′-CTTCTGTTACTGTGTGTAG-GATTGTTG-3′; and HK507, 5′-CTCTTCTAGTACTGGATGTTATATGGA-3′. The annealing temperature used for the 35-cycle PCR reaction was 62°C. To detect tumorigenesis, each mouse was physically examined twice a week, and the date of detecting palpable tumors was recorded. Mice were sacrificed when diameters of primary tumors reached 2 cm. For immunohistochemical analysis of proliferating cells, mice were injected i.p. with bromodeoxyuridine (BrdUrd, 50 μg/g body weight) at 2 h before sacrifice.

Cell cultures. Mouse embryonic fibroblasts (MEF) were isolated from day 12.5 mouse embryos and cultured as previously described (29). To determine cumulative population doublings, MEFs were cultured according to a 3T3 protocol, inoculated at the density of 3 × 10^4 per 25-cm² area (60-mm dish), and subcultured every 3 days. The population doubling level during each passage was calculated according to the formula: log[final cell number/initial cell number]. MEF-10A cells were cultured in DMEM/F12 supplemented with 5% heat-inactivated horse serum, 10 μg/mL insulin, 0.5 μg/mL hydrocortisone, 20 ng/mL recombinant epithelial growth factor, 2 mmol/L L-glutamine, and 100 μg/mL penicillin/streptomycin. The sequences of small interfering RNAs (siRNA) 1 and 3 for targeting Cdc25A were 5′-AACCUUGACAACCGAUGCA-3′ (residues 179–198) and 5′-CTTCTGTTACTGTGTGTAG-GATTGTTG-3′; and HK507, 5′-CTCTTCTAGTACTGGATGTTATATGGA-3′. The annealing temperature used for the 35-cycle PCR reaction was 62°C. To detect tumorigenesis, each mouse was physically examined twice a week, and the date of detecting palpable tumors was recorded. Mice were sacrificed when diameters of primary tumors reached 2 cm. For immunohistochemical analysis of proliferating cells, mice were injected i.p. with bromodeoxyuridine (BrdUrd, 50 μg/g body weight) at 2 h before sacrifice.

Figure 1. Heterozygous disruption of the Cdc25A gene results in decreased levels of CDC25A protein and increased tyrosine phosphorylation of CDK1 and CDK2. A, targeted disruption of murine Cdc25A gene. Targeting strategy for generation of Cdc25A-deficient mice is shown. B, Southern blotting and genomic PCR with tail DNA from a germ line heterozygous mutant and a wild-type littermate. C, Cdc25A expression and tyrosine phosphorylation of CDK1/2 in Cdc25A heterozygous MEFs. Bottom, Western blots (WB) of MEF extracts using the indicated antibodies. Top, Western blots of immunoprecipitates (IP) with control nonspecific IgG or specific IgG from MEF extracts. Cdk1/2-P, an antibody specific for Tyr58 phosphorylation of CDK1/2.

Results

Hemizygous disruption of Cdc25A results in modestly enhanced G₂ checkpoint and shortened proliferative life span. To determine the roles of CDC25A in development and oncogenesis, we generated a Cdc25A-deficient mouse line by standard gene targeting in embryonic stem cells (Fig. 1A and B). Exons 7...
Figure 2. Cell cycle progression is minimally affected in Cdc25A heterozygous MEFs, whereas checkpoint response to DNA damage is modestly enhanced. A, growth curves of Cdc25A+/+ and Cdc25A−/+ MEFs (passage 3) prepared from the same litter. B, cell cycle progression of serum-deprived Cdc25A+/+ and Cdc25A−/+ MEFs after stimulation. Cells pulse-labeled with BrdUrd for 30 min were analyzed by flow cytometry after staining with propidium iodide and anti-BrdUrd antibody. C, shortened proliferative life span of Cdc25A−/+ mouse embryonic fibroblasts. Cells with the indicated genotypes were cultured for continuous passages according to a 3T3 protocol (see Materials and Methods). Data representative of at least three independent cell preparations are shown. Bottom inset, Phase-microscopic pictures showing the morphology of MEFs at passage 12. D, enhanced G2 checkpoint in Cdc25A−/+ MEFs. MEFs were treated with ionizing irradiation (IR) at the indicated doses, followed by incubation at 30 min. Cells were then treated with nocodazole to block progression through metaphase. Two hours later, cells were fixed, stained with propidium iodide and anti-phospho-histone H3 antibody, and examined by flow cytometry. Percent decreases in mitotic populations of irradiated cultures, relative to nonirradiated controls, are shown as an indication of G2 checkpoint function. Columns, means from three different cell preparations; bars, SE.

Cdc25A+/- treated with ionizing irradiation (IR) decreased in mitotic populations of irradiated cultures, relative to nonirradiated controls, as shown by immuno-staining with an antibody specific for anti-phospho-histone H3. These observations are consistent with the notion that CDC25A mediates tyrosine dephosphorylation of CDK1 and CDK2. Cdc25A+/+ and Cdc25A−/+ MEFs at early passages showed similar proliferation rates (Fig. 2A) despite the changes in CDC25A levels and CDK1/2 phosphorylation. Cdc25A−/+ MEFs also exhibited normal kinetics of cell cycle entry from quiescence in response to serum stimulation (Fig. 2B, Supplementary Fig. S1). To further examine the replicative capacity of cells with hemizygous Cdc25A disruption, Cdc25A+/− and Cdc25A−/+ MEFs were continuously cultured according to a 3T3 protocol (Fig. 2C). Cdc25A+/− and Cdc25A−/+ MEFs exhibited comparable population doublings up to passage 8. Cdc25A−/+ MEFs ceased proliferation by passages 14 to 16. Cdc25A+/− MEFs slowed down proliferation significantly earlier, displaying typical senescent morphology by passages 9 and 10. These observations suggest that hemizygous loss of Cdc25A shortens proliferative life span of primary fibroblasts. We then examined G2 checkpoint response of Cdc25A+/− and Cdc25A−/+ MEFs to DNA damage (Fig. 2D) using an experimental scheme previously applied for the characterization of Cdc25B and Cdc25C knock-out MEFs (5). MEFs were treated with increasing doses of ionizing irradiation (IR), and then the ability of G2 cells to enter mitosis within 2 h after IR was monitored. At 30 min after IR, nocodazole was added into culture media to block cells at the prometaphase. At 120 min after IR, percentages of mitotic cells were determined by flow cytometry. IR decreased progression of G2 cells into mitosis, and the decrease was more remarkable in Cdc25A−/+ cultures, relative to that in Cdc25A+/− cultures. Levels of CDC25B or CDC25C were not significantly different between Cdc25A+/− and Cdc25A−/+ MEFs (data not shown), and their expression levels were unaltered. In contrast to the effect on G2 checkpoint, Cdc25A heterozygosity minimally affected G1 checkpoint, when Cdc25A−/+ MEFs synchronized by serum starvation were treated with IR and restimulated with serum (Supplementary Fig. S2). No significant differences in DNA synthesis were observed in exponentially proliferating Cdc25A−/+ and Cdc25A−/+ MEFs exposed to IR, suggesting no major change in intra-S checkpoint (data not shown). These results suggest that Cdc25A−/+ cells have modestly enhanced G2 checkpoint and shortened proliferating life span, whereas unperturbed cell cycle progression during early passages is essentially unaltered.

Heterozygous disruption of CDC25A inhibits cellular transformation. To assess cellular potential to undergo transformation,
and Cdc25A+/− MEFs were infected with a bicistronic retrovirus encoding H-ras V12 and a dominant negative p53 mutant (DNp53; ref. 30) and then analyzed by colony formation in soft agar. Cdc25A+/− MEFs formed significantly fewer colonies in soft agar in response to the transforming stimuli, compared with Cdc25A+/+ MEFs (Fig. 3A). Decreased susceptibility of Cdc25A+/− MEFs to transformation induced by H-rasV12 + DNp53 was also confirmed by focus formation assays in monolayer cultures (data not shown). These observations suggest that the cellular level of CDC25A is part of a rate-limiting mechanism of malignant transformation. To further delineate the role of CDC25A in transformation, we examined the effect of CDC25A knockdown in nontransformed human mammary epithelial MCF-10A cells. Two recombinant lentiviruses encoding different short hairpin RNAs, CDC25A shRNA 1 and 3, were used to knockdown CDC25A in MCF-10A cells. Lentiviral expression of shRNA 1 and 3 resulted in 57% and 35%
analyses for BrdUrd incorporation and Tyr 15 phosphorylation of CDK1/2 in with the indicated genotypes. CDK proteins. A, oncogene display hypoproliferation with increased tyrosine phosphorylation of CDK1/2. These data suggest that cellular CDC25A levels at the time of oncogene activation are critical and indicate that CDC25A plays a rate-limiting role in ras-mediated transformation.

Hemizygous loss of Cdc25A delays H-ras- or neu-induced mammary tumorigenesis. Cdc25A+/− mice exhibited normal development of all examined tissues, including mammary glands (Supplementary Fig. S3). We then addressed the question whether Cdc25A heterozygosity inhibits in vivo tumorigenesis, by cross-breeding Cdc25A+/− mice with MMTV-H-ras or MMTV-neu transgenic mice, which are well-established models for spontaneous mammary tumorigenesis (27, 28). Cdc25A+/−:MMTV-H-ras mice developed mammary and salivary tumors with average latency of 18 weeks (Fig. 4A). In striking contrast, the tumor latency of Cdc25A−/−:MMTV-H-ras mice was 60 weeks, demonstrating a marked delay in tumorigenesis. It is noteworthy that about 10% of Cdc25A+/−:MMTV-H-Ras mice did not develop detectable tumors over 2 years of monitoring. Cdc25A−/−:MMTV-neu mice also exhibited significantly delayed tumorigenesis, with median latency of 32 weeks, relative to the latency of 23 weeks in Cdc25A+/−:MMTV-neu mice (Fig. 4B). Thus, hemizygous loss of Cdc25A delays or inhibits ras- and neu-induced tumorigenesis. The macro- and microscopic morphologic characteristics and growth rates were indistinguishable between palpable (>0.5 cm) mammary adenocarcinomas induced by H-ras or neu in the Cdc25A+/− background and in Cdc25A−/− background (data not shown). To further characterize early events before tumor detection, we did whole-mount analyses of mammary tissues in virgin mice. Mammary glands from 12-week-old Cdc25A+/−:MMTV-neu mice showed proliferative disturbances as evidenced by hyperplastic nodules (Fig. 5A), which is in concordance with previous reports (28). Mammary glands from Cdc25A+/−:MMTV-neu mice exhibited grossly normal postnatal development of mammary epithelia, and focal proliferative lesions were less obvious. For a clue to the mechanism of the early changes rendered by Cdc25A heterozygosity, we then analyzed apoptosis and proliferation in mammary tissues from 5-week-old Cdc25A+/−; MMTV-neu and Cdc25A+/−;MMTV-neu mice (Fig. 5B). TUNEL analysis showed that there was no significant difference in apoptosis between the two groups. In contrast, percentages of S-phase cells, determined by BrdUrd immunohistochemistry, in mammary epithelia of Cdc25A+/−:MMTV-neu mice were significantly lower than those of Cdc25A+/−:MMTV-neu mice (8.65 ± 1.49% versus 26.4 ± 5.74%). Decreased proliferation in Cdc25A+/−:MMTV-neu mammary epithelia was correlated with increased immunoreactivities to the antibody specific to Tyr 15-phosphorylated CDK1/2. These data suggest that hemizygous loss of CDC25A is inhibitory on tumor initiation, mostly by down-regulation of proliferation stimulated by the neu-ras oncogenic pathway. The cell proliferation in mammary epithelia was almost comparable between Cdc25A−/− and Cdc25A+/− mice without MMTV-neu (7.47 ± 1.99% versus 6.85 ± 1.49%; Fig. 5C, Supplementary Fig. S4). These data clearly suggest that the cellular level of Cdc25A is critical for oncogene-induced cell proliferation.

decreases in cellular Cdc25A levels, respectively (Fig. 3B). These shRNAs did not significantly affect cellular levels of CDC25B or CDC25C and minimally affected the rate of proliferation (data not shown). To determine effects of CDC25A knockdown on transfor-

Figure 5. Mammary tissues of Cdc25A+/− mice expressing MMTV-neu oncogene display hypoproliferation with increased tyrosine phosphorylation of CDK proteins. A, whole-mount analysis of mammary glands from 12-week-old mice with the indicated genotypes. B, TUNEL assay and immunohistologic analyses for BrdUrd incorporation and Tyr 15 phosphorylation of CDK1/2 in mammary tissues of 5-week-old mice. C, the percentage of BrdUrd-positive cells in mammary epithelia of 5-week-old Cdc25A−/− and Cdc25A+/− mice in the presence and absence of neu oncogene are shown as a means + SE. *P = 0.006; **P = 0.007, statistically significant differences. The difference between Cdc25A+/− mice and Cdc25A−/−; MMTV-neu mice was not statistically significant (P = 0.315).
Finally, we examined the effect of Cdc25A heterozygosity on tumorigenesis initiated by another oncogenic signal, c-myc overexpression. Cdc25A+/− mice were crossbred with MMTV-myc transgenic mice, which is also a widely used murine mammary tumor model (27). In contrast to ras- and neu-induced tumorigenesis, the median tumor latency in Cdc25A+/−;MMTV-myc mice was not statistically different from that in Cdc25A+/+;MMTV-myc mice (44 weeks versus 40 weeks; Fig. 4C). Taken together, these in vivo effects of hemizygous CDC25A disruption suggest that cellular levels of CDC25A form a critical factor determining the efficacy of tumorigenesis initiated specifically by activation of the neu-ras oncogenic pathway.

Discussion

CDC25A activates multiple cyclin/CDK complexes throughout the cell cycle (5). The present study has shown that hemizygous disruption of the Cdc25A gene results in inhibition of ras-mediated transformation, although continuous cell cycle progression and serum-induced cell cycle entry are minimally affected. These observations suggest that the cellular level of CDC25A is rate limiting for malignant transformation that involves oncogenic action of ras. Consistently, tumorigenesis induced by the MMTV-H-ras or neu transgene is substantially delayed in Cdc25A+/− mice. The data showing that ~50% reduction in CDC25A expression is sufficient to inhibit tumor initiation indicate a critical role for CDC25A phosphatase in HER2/neu-ras–mediated mammary tumorigenesis. Cdc25A heterozygosity inhibits ras-induced tumorigenesis most remarkably and influences neu-induced tumorigenesis to a lesser extent. This difference implies that CDC25A activation is involved specifically in the ras–mitogen-activated protein kinase pathway, whereas other downstream targets of the Her2/neu oncogenic signal, e.g., the phosphoinositide-3-kinase-Akt pathway, may not depend on CDC25A. In contrast, Cdc25A heterozygosity had no significant effect on myc-induced tumorigenesis. These differential effects of the Cdc25A+/− background are reminiscent of those of cyclin D1 or Pin1 ablation. Both cyclin D1-null (Cnd1−/−) mice and Pin1-null (Pin1−/−) mice are refractory to MMTV-neu- and MMTV-H-ras-induced tumorigenesis, whereas they are sensitive to MMTV-myc-induced tumorigenesis (32, 33). Pin1 seems to function upstream of cyclin D1 in mammary tumorigenesis (33). The detail of the interplay of CDC25A and cyclin D1 in the neu-ras oncogenic pathway is yet to be elucidated. The major substrates of CDC25A are thought to be CDK1 and CDK2, and it remains unclear whether CDC25A activates cyclin D-CDK4/CDK6 complex during normal cell cycle progression or oncogenic transformation. Because CDC25A is an E2F target gene (34), cyclin D1 overexpression may result in the up-regulation of CDC25A via E2F activation. The unaltered sensitivity of Cdc25A+/− mice to myc-induced tumorigenesis implies that CDC25A does not play a key role in the oncogenic action of myc despite a previous report that CDC25A is a myc-target gene (35). It is possible that like Wnt-1, myc overexpression may induce oncogenesis in stem cells or very early progenitor cells in the mammary tissue. On the other hand, activation of the neu-ras pathway might transform more differentiated mammary epithelial cells, depending on cyclin D1 and CDC25A activation. Further investigations are necessary to fully understand the specificity of oncogenic pathways that require CDC25A function.

The present study, as well as previous studies using knockout mice, suggests diverse functions of the CDC25C family proteins. Cdc25A+/− mice are lethal during the peri-implantation period. Cdc25A+/− MEFs proliferate normally during early passages, but display modestly enhanced G2 checkpoint response to DNA damage and markedly decreased efficiency in ras-mediated transformation. Cdc25A+/− MEFs also undergo senescence at earlier passages than wild-type MEFs do. Decreased sensitivity of Cdc25A+/− MEFs to transforming signals could be associated with premature senescence, according to the recent notion that senescence induced by oncogenic or oxidative stress is a potent barrier against malignant transformation (36). On the other hand, no substantial effects of Cdc25A heterozygosity on apoptosis were observed when MEFs were exposed to IR or serum starved (data not shown). Consistently, in mammary tissues of Cdc25A+/−;MMTV-neu mice before tumor development, we observed decreased proliferation with increased Tyr15 phosphorylation, but no robust change in apoptosis. Thus, cells with reduced CDC25A expression seem to have impaired proliferative capacity in response to oncogenic stimuli or stress, whereas apoptotic responses seem to be unaltered. The inhibitory effect on proliferative capacity may account for the relative resistance of Cdc25A+/− mice to neu/ras-induced mammary tumorigenesis. Although CDC25A overexpression could affect apoptotic responses (37), the present study shows that hemizygous loss of CDC25A does not have major impacts on apoptotic control. In contrast with the phenotypes of Cdc25A knock-out mice, Cdc25B-null mice develop normally except for a meiotic defect during oogenesis (38). Cdc25C-null mice seem healthy (39). Interestingly, Cdc25B+/− MEFs and Cdc25C+/− MEFs exhibit no change in cell cycle progression or checkpoint function. Therefore, CDC25A plays a nonredundant role in embryogenesis and oncogenesis, whereas CDC25B and CDC25C are essentially dispensable. Although transgenic mice expressing CDC25B under the MMTV promoter display precocious alveolar hyperplasia (40) and modestly increased susceptibility to a carcinogen (41), it remains obscure whether CDC25B or CDC25C plays a rate-limiting role in oncogenesis. Taken together, among the CDC25 family, CDC25A is highlighted as an indispensable regulator of developmental and oncogenic proliferation.

Delayed tumorigenesis in the Cdc25A+/− background not only indicates the importance of CDC25A in tumor initiation, but also presents a scientific foundation for CDC25A as a potent therapeutic target. A clinical study reported that ~50% of T1a,b breast cancer tissues exhibited CDC25A overexpression, which correlated with poor survival (25). Our recent study showed that ectopic expression of CDC25A by an MMTV-CDC25A transgene significantly accelerates development of mammary tumors in MMTV-H-ras or MMTV-neu mice (42). Tumors with the MMTV-CDC25A transgene exhibit markedly accelerated growth and more invasive characteristics with chromosomal instability, which are consistent with the suggested role for CDC25A in malignant phenotypes of human breast cancer. Furthermore, the inhibitory effect of the Cdc25a−/− background on the ras-neu oncogenic pathway supports the rationale of using CDC25A inhibitors for therapeutic intervention. Multiple small-molecule agents including vitamin K analogues have been developed as pharmacologic inhibitors of CDC25 phosphatases (43–45). One of such CDC25 inhibitors, BNP2685, exhibits in vivo tumor inhibitory activity as an orally bioactive agent (46). Further investigations are needed to establish chemotherapeutic strategies targeted on CDC25 phosphatases, especially for breast cancer with Her2/neu overexpression. The
mouse models with altered CDC25A levels will be useful tools for examining biological impacts of CDC25-targeted therapeutic intervention.

Acknowledgments

Received 12/31/2006; revised 4/19/2007; accepted 5/10/2007.

Grant support: J. Jin from the National Cancer Institute (CA100204, CA112282, and HD38085), the Department of Defense (DAMD 17-02-1-0413), the Searle Leadership Fund, the Zell Scholar Fund, and the Robert H. Lurie Comprehensive Cancer Center.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Brian Zwecker, Suchitra Prasad, Alba Santana, Aileen Azuyl, Lida Aris, Kimberly Hansel, Shengliang Liang, Anne Shilkaitis, Jadwiga Labanowska, the Transgenic Facility of the University of Illinois at Chicago, and the Center for Women's Health and Reproduction (US4 HD46903) for technical assistance and resources. We also thank Alfred Bademker at the Biositistics Core of Robert H. Lurie Comprehensive Cancer Center for statistical analyses, Hidayatallah Munshi, Nissim Him, Philip Tyrus, Thomas McGarry, Jill Polling, Gobindran Dimri, Puneet Opal, Swapan Jinsawatnotai, David Moons, and Mary Gallam for helpful suggestions and discussions.

References


Hemizygous Disruption of Cdc25A Inhibits Cellular Transformation and Mammary Tumorigenesis in Mice

Dipankar Ray, Yasuhisa Terao, Dipali Nimbalkar, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/67/14/6605

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2007/07/23/67.14.6605.DC1

Cited articles
This article cites 46 articles, 23 of which you can access for free at:
http://cancerres.aacrjournals.org/content/67/14/6605.full.html#ref-list-1

Citing articles
This article has been cited by 13 HighWire-hosted articles. Access the articles at:
/content/67/14/6605.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.